Abstract
The prognosis for malignant gliomas remains poor despite multimodality therapy. An increased understanding of the molecular pathogenesis involved in glioma development and growth has resulted in development of agents that specifically target these molecular processes and pathways. Except for inhibitors of the vascular endothelial growth factor pathway, results from most single agent trials have been modest at best. Tailoring therapy to the individual patients is an attractive strategy although most studies have failed to determine predictive biomarkers. Numerous novel agents, multitargeted agents, and combination therapies are now in clinical trials for malignant glioma.
Keywords: Targeted therapy, malignant glioma, angiogenesis, clinical trials, multi-targeted therapy, "malignant gliomas", cellular signaling kinases
Current Signal Transduction Therapy
Title:Application of Targeted Therapy to Malignant Gliomas and Response to Treatment
Volume: 8 Issue: 1
Author(s): Eudocia Q. Lee, Andrew D. Norden, Jan Drappatz and Patrick Y. Wen
Affiliation:
Keywords: Targeted therapy, malignant glioma, angiogenesis, clinical trials, multi-targeted therapy, "malignant gliomas", cellular signaling kinases
Abstract: The prognosis for malignant gliomas remains poor despite multimodality therapy. An increased understanding of the molecular pathogenesis involved in glioma development and growth has resulted in development of agents that specifically target these molecular processes and pathways. Except for inhibitors of the vascular endothelial growth factor pathway, results from most single agent trials have been modest at best. Tailoring therapy to the individual patients is an attractive strategy although most studies have failed to determine predictive biomarkers. Numerous novel agents, multitargeted agents, and combination therapies are now in clinical trials for malignant glioma.
Export Options
About this article
Cite this article as:
Q. Lee Eudocia, D. Norden Andrew, Drappatz Jan and Y. Wen Patrick, Application of Targeted Therapy to Malignant Gliomas and Response to Treatment, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010004
DOI https://dx.doi.org/10.2174/1574362411308010004 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy The Return of the INGs, Histone Mark Sensors and Phospholipid Signaling Effectors
Current Drug Targets Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Gliomagenesis and the Use of Neural Stem Cells in Brain Tumor Treatment
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) Focus on the Use of Resveratrol as an Adjuvant in Glioblastoma Therapy
Current Pharmaceutical Design Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Isolation, Purification and Characterization of a Novel Steroidal Saponin Cholestanol Glucoside from Lasiodiplodia theobromae that Induces Apoptosis in A549 Cells
Anti-Cancer Agents in Medicinal Chemistry Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
Current Pharmaceutical Design Small-Molecule Inhibitors of Bcl-2 Family Proteins as Therapeutic Agents in Cancer
Recent Patents on Anti-Cancer Drug Discovery PET Imaging for Gene & Cell Therapy
Current Gene Therapy